Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a drug for acromegaly protect kidneys in polycystic disease?

NCT ID NCT02127437

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether lanreotide, a drug that blocks certain growth hormones, can slow the loss of kidney function in people with autosomal dominant polycystic kidney disease (ADPKD). The study included 159 adults with moderate kidney decline. Participants received either lanreotide injections or a placebo every 4 weeks for 3 years. The main goal was to see if lanreotide could reduce the rate of kidney function decline by at least 30%.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lanreotide
What this could lead to
If successful, lanreotide could offer a new treatment to slow kidney function loss in people with ADPKD, potentially delaying the need for dialysis or transplant.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely confirmed. Lanreotide may not slow kidney decline enough to be clinically meaningful, and side effects like gallstones or injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

159 people

The number who actually took part.

Started

Sep 2014

Finished

Jul 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * autosomal dominant polycystic kidney disease (clinical, familial, imaging grounds) * measured GFR : 30 to 89 ml/mn/1.73m2 * age \> 18 * affiliated with health insurance * written informed consent Exclusion Criteria: * iohexol /iodine allergy * diabetes mellitus * other associated nephropathy suspected * evolutive or recent malignant disease ( in the previous 5 years) * cholelithiasis * uncontrolled hypertension (BP\>160/100 mmHg) * cardiac failure of grade III or IV according to the NYHA (New York Heart Association) classification * liver failure * psychiatric illness * pregnancy, lactation, lack of contraception * use of somatostatin analogs during the last 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autosomal dominant polycystic kidney disease (adpkd) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autosomal dominant polycystic kidney disease (adpkd)

Contacts and locations

Locations

  • Necker hospital

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.